Virus News and Research

Latest Virus News and Research

Pharmasset reports net loss of $19.9 million for quarter ended March 31, 2011

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2011.

25 Apr 2011

Avian flu remains endemic in six countries, could take at least a decade to eradicate, FAO says

It will take at least 10 years to eradicate the H5N1 virus from poultry in the six countries where it is endemic, the U.N. Food and Agriculture Organization said in a report released on Thursday, Agence France-Presse reports.

25 Apr 2011

Recent releases in Global Health

When health ministers gather for the World Health Assembly in May they will try to come up with a solution to "a dilemma that has dogged decision-makers for decades - whether and when to destroy the last remaining stocks of the smallpox virus," David Heymann and Emma Ross, both of the Global Health Security Centre at Chatham House, write in an article in The World Today.

25 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Research solves challenging problem of industry-scale production of large RNA molecules

Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.

22 Apr 2011

New study: Children born with HIV are now faring well into adolescence, adulthood

Once facing an almost certain death sentence, most children born with HIV are now faring well into adolescence and adulthood, according to a newly published study co-authored by Tulane infectious diseases expert Dr. Russell Van Dyke. The study was published in the Journal of Acquired Immune Deficiency Syndromes.

22 Apr 2011

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

The Healthy Home, a new book providing simple solutions for reducing toxins and other health hazards in the home, has advanced in ranking on several national best sellers lists within a month of publication. After becoming a Top 100 Amazon.com best seller following its first week of sales, The Healthy Home, released on March 22, quickly hit the New York Times, USA TODAY, Publishers Weekly and L.A. Times best sellers lists.

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

GM-SCF therapy can reduce flu symptoms and prevent death

New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor significantly reduces flu symptoms and prevents death after a lethal dose influenza virus.

22 Apr 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

One in eight children living with HIV/AIDS "experiences triple-class virological failure - meaning the virus becomes resistant to multiple drugs - within five years of starting antiretroviral treatment," according to a study published Wednesday in the Lancet, HealthDay News/MSN reports. The "failure rate is higher than in adults and highlights the challenge of maintaining viral load suppression in young patients who begin antiretroviral therapy so early in life, the researchers said," according to the news service (Preidt, 4/19).

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

TRIM5 cellular protein helps rhesus monkeys resist HIV

Thanks to a certain protein, rhesus monkeys are resistant to HIV. Known as TRIM5, the protein prevents the HI virus from multiplying once it has entered the cell. Researchers from the universities of Geneva and Zurich have now discovered the protein's mechanism, as they report in Nature. This also opens up new prospects for fighting HIV in humans.

21 Apr 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics Biotech Inc. today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK.

20 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

Study shows possibility of women living with AIDS to breastfeed with lower risk

In low-income countries, 1.4 million women are living with the Aids virus. If no prevention measures are taken, the risk for future mothers of transmitting HIV to their child in utero, during delivery or when breastfeeding is 35%.

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Virus News and Research

Latest Virus News and Research

Pharmasset reports net loss of $19.9 million for quarter ended March 31, 2011

Avian flu remains endemic in six countries, could take at least a decade to eradicate, FAO says

Recent releases in Global Health

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Research solves challenging problem of industry-scale production of large RNA molecules

New study: Children born with HIV are now faring well into adolescence, adulthood

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

Researchers discover new compound to fight against shingles

GM-SCF therapy can reduce flu symptoms and prevent death

FDA warns four firms to stop making unproven MRSA prevention claims

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

Biogen Idec first quarter revenues increase 9% to $1.2 billion

TRIM5 cellular protein helps rhesus monkeys resist HIV

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

Study shows possibility of women living with AIDS to breastfeed with lower risk

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in